BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...

The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...

Results for the Phase I clinical trial, published in the New England Journal of Medicine, bring hope for people with ...

BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a ...

UK: A recent retrospective cohort study has highlighted the critical role of kidney function in patients diagnosed with ...

The stock market responded positively to the company's announcement, with its share price leaping more than 28% following the ...

The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...

See the new treatment that will break a Pfizer monopoly on a drug for heart disease.

BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved ...

Vutrisiran, a transthyretin-directed small interfering RNA therapeutic, is currently approved under the brand name Amvuttra ® for the treatment of polyneuropathy manifestations of hereditary ...

Attruby (acoramidis) is a small molecule approved to treat adults with transthyretin amyloid cardiomyopathy. It will have a ...

The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...